Coronary Artery Disease Clinical Trial
— EXCELLENTOfficial title:
Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions
Verified date | June 2010 |
Source | Seoul National University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | South Korea: Institutional Review Board |
Study type | Interventional |
Objectives
1. To evaluate the safety and long-term effectiveness of coronary stenting with the
Everolimus-eluting coronary stent system(EECSS) (XIENCETM V, Abbott Vascular, Santa
Clara, CA, PromusTM, Boston Scientific, Natick, MA), compared with the
sirolimus-eluting coronary stent system(SECSS) (CypherTM, Cordis Johnson & Johnson,
Warren, NJ) in the treatment of coronary stenosis.
2. To evaluate the safety and efficacy of 6-month clopidogrel therapy compared with
12-month clopidogrel therapy.
Study Design: Prospective, open label, two-arm, randomized multi-center trial to test the
non-inferiority of EECSS compared with the SECSS, and to test the non-inferiority of 6
months duration compared with 12 months duration of clopidogrel therapy. Patients will be
randomized in a two by two factorial manner according to the type of drug eluting stent
(EECSS vs. SECSS) and the duration of dual anti-platelet therapy (6 months vs. 12 months).
Randomization will also be stratified per hospital for the presence of DM and the presence
of long lesions (lesion length ≥ 28mm)
Patient Enrollment: 1,372 patients enrolled at 17 centers in Korea.
Patient Follow-Up: Clinical follow-up will occur at 1, 3, and 9 months, and at 1, 2, 3, 4,
and 5 years. Investigator or designee may conduct follow-up as telephone contacts or office
visits.
Primary Endpoint
- In-segment late luminal loss (LL) at 9 months for comparison of stenting with EECSS vs.
SECSS.
- Target vessel failure (TVF) (cardiac death, myocardial infarction, ischemia driven
target vessel revascularization) at 12 months for comparison of 6 months vs. 12 months
of clopidogrel therapy
Secondary Endpoint
- All Death
- Cardiac death
- Myocardial infarction
- Target vessel revascularization (TVR) (all and ischemia-driven)
- Target lesion revascularization (TLR) (all and ischemia-driven)
- Stent thrombosis
- Acute success (device, lesion, and procedure)
- Bleeding
- Cerebrovascular accident
- In-stent LL at 9 months
- Angiographic pattern of restenosis at 9-month angiographic follow-up
- In-stent and in-segment % diameter stenosis (%DS) at 9 months
- In-stent % volume obstruction (%VO) at 9 months
- Incomplete stent apposition post index procedure
- Persisting incomplete stent apposition, late-acquired incomplete stent apposition,
aneurysm, thrombosis, and persisting dissection at 9 months
Status | Active, not recruiting |
Enrollment | 1466 |
Est. completion date | April 2014 |
Est. primary completion date | April 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
General Inclusion Criteria: 1. Subject must be at least 18 years of age. 2. Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving the XIENCE V EECS and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure. 3. Subject must have significant coronary artery stenosis (>50% by visual estimate) 4. Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina, recent infarction, silent ischemia, positive functional study or a reversible changes in the electrocardiogram (ECG) consistent with ischemia. In subjects with coronary artery stenosis > 75%, evidence of myocardial ischemia does not have to be documented. 5. Subjects must be an acceptable candidate for Coronary Artery Bypass Graft (CABG) surgery. Angiographically Inclusion Criteria 1. Target lesion(s) must be located in a native coronary artery with visually estimated diameter of = 2.25 mm and = 4.25 mm. 2. Target lesion(s) must be amenable for percutaneous coronary intervention General Exclusion Criteria: 1. The patient has a known hypersensitivity or contraindication to any of the following medications (heparin, aspirin, clopidogrel, sirolimus, everolimus, Contrast media 2. Systemic (intravenous) Sirolimus, everolimus use within 12 months. 3. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study. 4. History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions. 5. Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months. 6. Current known current platelet count <100,000 cells/mm3 or Hgb <10 g/dL. 7. An elective surgical procedure is planned that would necessitate interruption of clopidogrel during the first 12 months post enrollment. 8. Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment). 9. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period. 10. Patients who have received any stent implantation in the target vessel prior to enrollment. 11. Patients with LVEF<25% or those with cardiogenic shock 12. Patients with myocardial infarction within 72 hours 13. Creatinine level = 3.0mg/dL or dependence on dialysis. 14. Severe hepatic dysfunction (AST and ALT: 3 times upper normal reference values). Angiographic Exclusion Criteria 1. Patients with significant left main coronary artery stenosis 2. Patients who's target lesion has in-stent restenosis at the stented segment of drug-eluting stents or bare metal stents 3. Target lesions with chronic total occlusion 4. True bifurcation lesions requiring two stents |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Hospital | Seoul | 28 Yongon Dong, Jongro Gu |
Lead Sponsor | Collaborator |
---|---|
Seoul National University Hospital | Abbott, Boston Scientific Corporation |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | In-segment late luminal loss (LL) at 9 months for comparison of stenting with EECSS vs. SECSS. | 9 months | Yes | |
Primary | Target vessel failure (TVF) (cardiac death, myocardial infarction, ischemia driven target vessel revascularization) at 12 months for comparison of 6 months vs. 12 months of clopidogrel therapy | 12 months | Yes | |
Secondary | All death | 5 years | Yes | |
Secondary | Cardiac death | 5 Years | Yes | |
Secondary | Myocardial infarction | 5 years | Yes | |
Secondary | Target vessel revascularization (TVR) (all and ischemia-driven) | 5 years | Yes | |
Secondary | Target lesion revascularization (TLR) (all and ischemia-driven) | 5 years | Yes | |
Secondary | Stent thrombosis | 5 years | Yes | |
Secondary | Acute success (device, lesion, and procedure) | Index procedure | Yes | |
Secondary | Bleeding | 5 years | Yes | |
Secondary | Cerebrovascular accident | 5 years | Yes | |
Secondary | In-stent LL at 9 months | 9 months | Yes | |
Secondary | Angiographic pattern of restenosis at 9-month angiographic follow-up | 9 months | Yes | |
Secondary | In-stent and in-segment % diameter stenosis (%DS) at 9 months | 9 months | Yes | |
Secondary | In-stent % volume obstruction (%VO) at 9 months | 9 months | Yes | |
Secondary | Incomplete stent apposition post index procedure | Index procedure | No | |
Secondary | Persisting incomplete stent apposition, late-acquired incomplete stent apposition, aneurysm, thrombosis, and persisting dissection at 9 months | 9 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |